Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2020
ADC Therapeutics reports second-quarter 2020 results
ADC Therapeutics reported financial results for the second quarter ended June 30, 2020, including a net loss of $126.6 million.
2020
ADC Therapeutics receives first credit-facility tranche
ADC Therapeutics announced receipt of the initial $65.0 million disbursement under its previously announced convertible credit facility with Deerfield and the issuance to Deerfield of $65.0 million in senior secured convertible notes.
2020
ADC Therapeutics appoints Jennifer Creel as CFO
ADC Therapeutics announced the appointment of Jennifer Creel as its Chief Financial Officer. Creel joins the company from Celgene Corporation.